Products for Research Use Only
RegisterLogin

Icatibant (Standard)

CAT: 0804-HY-17446R-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17446R-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Icatibant (Standard) is the analytical standard of Icatibant. This product is intended for research and analytical applications. Icatibant (HOE-140) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively[1][2][3].
CAS Number
130308-48-4
Product Name Alternative
HOE 140 (Standard)
UNSPSC
12352209
Target
Bradykinin Receptor; Reference Standards
Type
Reference Standards
Related Pathways
GPCR/G Protein; Others
Field of Research
Endocrinology
Assay Protocol
https://www.medchemexpress.com/icatibant-standard.html
Smiles
[H][C@]1(C[C@@H](C(N[C@H](C(O)=O)CCCNC(N)=N)=O)N2C([C@@H]3N(C([C@H](CO)NC([C@H](CC4=CC=CS4)NC(CNC([C@@H]5C[C@@H](O)CN5C([C@H]6N(C([C@H](CCCNC(N)=N)NC([C@H](N)CCCNC(N)=N)=O)=O)CCC6)=O)=O)=O)=O)=O)CC7=C(C=CC=C7)C3)=O)[C@]2([H])CCCC1
Molecular Formula
C59H89N19O13S
Molecular Weight
1304.52
References & Citations
[1]Hock FJ, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991 Mar;102 (3) :769-73.|[2]Y Arai, et al. Effect of Icatibant, a Bradykinin B2 Receptor Antagonist, on the Development of Experimental Ulcerative Colitis in Mice. Dig Dis Sci. 1999 Apr;44 (4) :845-51.|[3]Marie-Thérèse Bawolak, et al The Bradykinin B2 Receptor Antagonist Icatibant (Hoe 140) Blocks Aminopeptidase N at Micromolar Concentrations: Off-Target Alterations of Signaling Mediated by the Bradykinin B1 and Angiotensin Receptors. Eur J Pharmacol. 2006 Dec 3;551 (1-3) :108-11.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Chemical Information

Icatibant

Icatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B2 receptors with a similar affinity to bradykinin. It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B2 receptors antagonists, thus representing a new class of medication. It was investigated as a potential treatment of hereditary angioedema (HAE) as bradykinin was implicated in HAE swelling; specifically, mice lacking B2 receptors showed reduced swelling, thus demonstrating bradykinin involvement in the disease pathophysiology. Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. The FDA approval was based on positive results obtained from 3 double-blind, randomized, controlled clinical trials known as FAST 1, 2, and 3, where a median time to almost complete symptom relief was observed to be 8 hours compared to 36 hours for the placebo treatment.

CAS Number130308-48-4
PubChem CID6918173
IUPAC Name(2S)-2-[[(2S,3aS,7aS)-1-[(3R)-2-[(2S)-2-[[(2S)-2-[[2-[[(2S,4R)-1-[(2S)-1-[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
Molecular FormulaC59H89N19O13S
Molecular Weight1304.5
XLogP-6.4
Topological Polar Surface Area552
Hydrogen Bond Donor Count15
Hydrogen Bond Acceptor Count18
Rotatable Bond Count30
Heavy Atom Count92
Formal Charge0
Complexity2720
SMILES
C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@H]3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
InChI
InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1
InChIKey
QURWXBZNHXJZBE-SKXRKSCCSA-N
Chemical Structure
2D Structure
2D structure of Icatibant
CAS: 130308-48-4
CID: 6918173
Formula: C59H89N19O13S
MW: 1304.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight1304.5
XLogP3-6.4
Hydrogen Bond Donor Count15
Hydrogen Bond Acceptor Count18
Rotatable Bond Count30
Exact Mass1303.66079514
Monoisotopic Mass1303.66079514
Topological Polar Surface Area552 Ų
Heavy Atom Count92
Formal Charge0
Complexity2720
Isotope Atom Count0
Defined Atom Stereocenter Count12
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-108896R-01Icatibant (acetate) (Standard)
HY-17446-01Icatibant
HY-108896-01Icatibant (acetate)
HY-P2274RArgifin (Standard)
HY-N9362REmodinanthrone (Standard)
HY-N7948RIsomaltotetraose (Standard)
HY-N7640RDeoxylimonin (Standard)
HY-N7617RToralactone (Standard)
HY-N7541RAntrodin A (Standard)
HY-N6739RBeauvericin (Standard)

Alternative Products

CatalogName
FI45882-01Icatibant
T22344-01Icatibant Acetate
A18074-5Icatibant 5mg
A18074-1Icatibant 1mg
A18074-10Icatibant 10mg

Popular Products